Compare MAIN & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAIN | APGE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.7B |
| IPO Year | 2007 | 2023 |
| Metric | MAIN | APGE |
|---|---|---|
| Price | $64.09 | $80.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $61.57 | ★ $101.89 |
| AVG Volume (30 Days) | 598.4K | ★ 984.9K |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | ★ 6.75% | N/A |
| EPS Growth | ★ 9.38 | N/A |
| EPS | ★ 6.03 | N/A |
| Revenue | ★ $561,290,000.00 | N/A |
| Revenue This Year | $5.53 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | ★ 5.92 | N/A |
| 52 Week Low | $47.00 | $26.20 |
| 52 Week High | $67.77 | $84.56 |
| Indicator | MAIN | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 64.23 | 65.08 |
| Support Level | $60.40 | $75.02 |
| Resistance Level | $64.59 | $84.56 |
| Average True Range (ATR) | 1.37 | 3.53 |
| MACD | 0.24 | -0.03 |
| Stochastic Oscillator | 89.88 | 70.71 |
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancing, and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants, and other securities of the lower middle market and middle market companies based in the United States. Business functioned through the U.S. region and it derives the majority of its income from the source of fees, commission, and interest.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.